Martin Renner, CEO of Develco and Helene Rey, Research and Development
The art of creative drug formulation from active pharmaceutical ingredients (APIs) requires technical expertise and utmost precision. Innovative dosage forms or delivery systems direct a drug to its specific site of action and optimise the timing of the drug release. While enhancing patient comfort and convenience, these innovations can increase efficacy and promote better health care. Against this backdrop, Swiss-German pharmaceutical company Develco Pharma specialises in developing and manufacturing orally-administered modified release drugs and prolonged/ chrono-release drug delivery systems. Develco provides licenses of its curated products to international pharmaceutical companies for commercialization in their respective markets.
Renowned for accomplishing complex drug formulation, Develco identifies and defines pharmaceutical products containing known active ingredients and develops generic, hybrid, value-added, repurposed and innovative formulations backed by clinical data for the delayed or modified release of the active ingredient.
“At Develco, we bring value to the customers through full-fledged development of products with special formulations,” says Martin Renner, CEO of Develco.
Develco possesses a state-of-the-art commercial production facility in Southern Germany, currently focused on narcotic and non-narcotic products. With digital technologies, the company manufactures essential regular-use bioequivalent medicines for customers. The company also has a pilot plant in Switzerland for process development and production of material for their clinical trials. They specialise in oral solid dosage forms with special release criteria. The drug development portfolio ranges from simple mixing, pressing, encapsulation, and film coating processes to producing highly complex pellets and retarding solid forms.
Develco focuses on sustained, modified release formulations in the manufacturing process and leverages different available technologies. Develco utilises Multiple-Unit Pellet System (MUPS) tablets to facilitate a successful dosage form for modified drug release and deploys granulation processes to produce matrix tablets. Develco is also extending its product portfolio to meet demands for drugs in treating several therapeutic areas, including Central Nervous System (CNS) with a focus on severe pain and ADHD.
A one-stop shop for customers, the team at Develco assists clients through the value chain from development to supply. The development process comprises experiments for appropriate formulations, validation of analytical methods, stability testing, clinical and commercial manufacture, and leading clinical trials to show the in vivo product performance. Supported by a team of experts, Develco also encourages effective collaboration among multiple specialised departments.
At Develco, we bring value to the customers through full-fledged development of products with special formulations
Due to its expertise and innovation in developing complex drugs, Develco has garnered a significant customer base, including global pharmaceutical groups. For instance, Develco has also developed products that show similar properties as the original osmotic-release oral system (OROS) formulation from a clinical and API release profile perspective. One of the company’s customers is very successful marketing it as a differentiated generic drug.
Develco’s drug development is characterised by its creative and innovative approach. Develco believes in and lives fast-tracking all the steps involved in drug development to cater to customer and patient needs at the earliest. Based on its innovation and expertise, Develco has emerged as an internationally recognised pharmaceutical provider for fast track development and commercial supplies. The company has 180 market approvals in Europe, the U.S., the Middle East, South Africa, Asia, and Australia.
Develco, with its rich experience and modern drug formulation technology, has all the right ingredients for further successful expansion.